Contact Us

    • 1-631-466-5530
      44-207-097-1828
    • 1-631-207-8356
    • 45-1 Ramsey Road, Shirley, NY 11967, USA
    • Global Locations

Oncolytic Viruses in Hepatocellular Carcinoma Treatment

Introduction of Hepatocellular Carcinoma (HCC)

HCC is one of the most common and lethal malignancies worldwide. It is more frequent among men than women, and the morbidity increases gradually with age. More than one million worldwide cases of HCC occur each year. Surgical operation, liver transplantation, and ablative therapies are usually curative for early stages of HCC; systemic pharmacotherapy is usually the final and main treatment for advanced-stage disease. However, chemotherapy shows poor response rates in patients with advanced-stage HCC. Sorafenib is widely used in the standard systemic treatment for HCC patients with HCC, but the tumor response rate is unsatisfactory. Besides sorafenib, other target agents, such as sunitinib, linifanib, or brivanib have not been proven to be superior to sorafenib. Therefore, HCC is considered a highly refractory cancer and is resistant to conventional chemotherapy. There is an urgent need for a new approach for the treatment of HCC.

Oncolytic Viruses in Hepatocellular Carcinoma Treatment

Oncolytic Viruses for the Treatment of HCC

Oncolytic viruses have been recently recognized as an effective treatment for cancer in preclinical models and promising clinical responses in human cancer patients. Oncolytic viruses have a number of advantages over conventional antitumor agents, because they have their cancer specificity and better safety margin. Adenovirus and vaccinia virus are mostly used for HCC treatment in clinical trials.

Oncolytic virotherapy has shown promising results in treating HCCs and the effects can be more enhanced by oncolytic virus engineering. Creative Biolabs has successfully established OncoVirapy™ platform to provides a one-stop solution of oncolytic virus engineering.

Reference

  1. Yoo, S.Y.; et al. Oncolytic virus-based immunotherapies for hepatocellular carcinoma. Mediators of inflammation. 2017, 2017.

Please feel free to contact us for a quote and further discussion with our scientists.

All services and products are for lab research only, not for any clinical use.

Online Inquiry

  • Verification code
    Click image to refresh the verification code.

Contact Us

  • 1-631-466-5530
    44-207-097-1828
  • 1-631-207-8356

Contact Us

Copyright © 2007 - 2021 Creative Biolabs. All Rights Reserved